Table 3.
Treatment and renal outcomes of the adult HSPN patients
| Items | Values (n = 698) |
|---|---|
| Treatment | |
| Methylprednisolone pulse treatment, n (%) | 166 (23.8) |
| Prednisone, n (%) | 474 (67.9) |
| Prednisone + tripterysium glycosides, n (%) | 272 (39.0) |
| Prednisone + leflunomide, n (%) | 14 (2.0) |
| Prednisone + mycophenolate mofetil, n (%) | 98 (14.0) |
| Follow-up | |
| Follow-up from biopsy, months | 54.0 (34.0–78.0) |
| TA-P (g/day) | 0.45 (0.30–0.74) |
| <0.4 g/day, n (%) | 295 (42.3) |
| 0.4–1.0 g/day, n (%) | 290 (41.5) |
| >1.0 g/day, n (%) | 113 (16.2) |
| TA-RBC (×104/mL) | 35 (14–87) |
| TA-MAP (mmHg) | 91.0 (85.0–97.0) |
| Outcomes | |
| ESRD, n (%) | 32 (4.6) |
| ESRD or a 50% decline in renal function, n (%) | 53 (7.6) |
TA-P time-average proteinuria; TA-RBC time-average microscopic hematuria;
TA-MAP time-average mean arterial pressure; ESRD end-stage renal disease.